The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
Open accessAbstract
BACKGROUND: Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well understood, limiting progress in therapy development and research. LAD intrinsic molecular subtypes are a validated stratification of naturally-occurring gene expression patterns and encompass different functional pathways and patient outcomes. Patients may have incurred different mutations and alterations that led to the different subtypes. We hypothesized that the LAD molecular subtypes co-occur with distinct mutations and alterations in patient tumors. METHODOLOGY/PRINCIPAL FINDINGS: The LAD molecular subtypes (Bronchioid, Magnoid, and Squamoid) were tested for association with gene mutations and DNA copy number alterations using statistical methods and published cohorts (n = 504). A novel validation (n = 116) cohort was assayed and interrogated to confirm subtype-alteration associations. Gene mutation rates (EGFR, KRAS, STK11, TP53), chromosomal instability, regional copy number, and genomewide DNA methylation were significantly different among tumors of the molecular subtypes. Secondary analyses compared subtypes by integrated alterations and patient outcomes. Tumors having integrated alterations in the same gene associated with the subtypes, e.g. mutation, deletion and underexpression of STK11 with Magnoid, and mutation, amplification, and overexpression of EGFR with Bronchioid. The subtypes also associated with tumors having concurrent mutant genes, such as KRAS-STK11 with Magnoid. Patient overall survival, cisplatin plus vinorelbine therapy response and predicted gefitinib sensitivity were significantly different among the subtypes. CONCLUSIONS/ SIGNIFICANCE: The lung adenocarcinoma intrinsic molecular subtypes co-occur with grossly distinct genomic alterations and with patient therapy response. These results advance the understanding of lung adenocarcinoma etiology and nominate patient subgroups for future evaluation of treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Self-citationConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Self-citationStratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Self-citationMonti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003) · Machine Learning · doi:10.1023/a:1023949509487 · Cited by 2,116 · cited 1×
“These were reviewed to determine the k that first approaches the maximum consensus, which indicates the most stable cluster total and indicates that further increases in k are insubstantially improving consensus [28,48].”
BackgroundGene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Diversity of gene expression in adenocarcinoma of the lung
Garber, M. E., Troyanskaya, O. G., Schluens, K., Petersen, S., Thaesler, Z., Pacyna-Gengelbach, M., van de Rijn, M., Rosen, G. D., Perou, C. M., Whyte, R. I., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241500798 · Cited by 1,298
Self-citationDirector's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma (2008) · Nature Medicine · doi:10.1038/nm.1790 · Cited by 1,190
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
Weigman, V. J., Chao, H.-H., Shabalin, A. A., He, X., Parker, J. S., Nordgard, S. H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1846-y · Cited by 902
Self-citationThe BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
(2016) · Diagnostic Imaging: Nuclear Medicine · doi:10.1016/b978-0-323-37753-9.50111-0 · Cited by 855
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Ganti, A. K. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 730
DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer
Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glöckner, S., Piantadosi, S., Gabrielson, E., Pridham, G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706550 · Cited by 593
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., Milton, D. T., Strawn, J. R., Wakelee, H. A., & Giaccone, G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8923 · Cited by 486
Zhu, C.-Q., Ding, K., Strumpf, D., Weir, B. A., Meyerson, M., Pennell, N., Thomas, R. K., Naoki, K., Ladd-Acosta, C., Liu, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4325 · Cited by 471
High-resolution genomic profiles of human lung cancer
Tonon, G., Wong, K.-K., Maulik, G., Brennan, C., Feng, B., Zhang, Y., Khatry, D. B., Protopopov, A., You, M. J., Aguirre, A. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504126102 · Cited by 394
Motoi, N., Szoke, J., Riely, G. J., Seshan, V. E., Kris, M. G., Rusch, V. W., Gerald, W. L., & Travis, W. D. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31815cb162 · Cited by 371
Takeuchi, T., Tomida, S., Yatabe, Y., Kosaka, T., Osada, H., Yanagisawa, K., Mitsudomi, T., & Takahashi, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8224 · Cited by 355
Hayes, D. N., Monti, S., Parmigiani, G., Gilks, C. B., Naoki, K., Bhattacharjee, A., Socinski, M. A., Perou, C., & Meyerson, M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1748 · Cited by 314
Self-citationLindgren, D., Frigyesi, A., Gudjonsson, S., Sjödahl, G., Hallden, C., Chebil, G., Veerla, S., Ryden, T., Månsson, W., Liedberg, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4213 · Cited by 310
Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data
Liu, Y., Hayes, D. N., Nobel, A., & Marron, J. S. (2008) · Journal of the American Statistical Association · doi:10.1198/016214508000000454 · Cited by 267
Self-citationPredicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Janku, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 249
Carretero, J., Shimamura, T., Rikova, K., Jackson, A. L., Wilkerson, M. D., Borgman, C. L., Buttarazzi, M. S., Sanofsky, B. A., McNamara, K. L., Brandstetter, K. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.026 · Cited by 243
Self-citationTomida, S., Takeuchi, T., Shimada, Y., Arima, C., Matsuo, K., Mitsudomi, T., Yatabe, Y., & Takahashi, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7053 · Cited by 242
EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma
Yatabe, Y., Kosaka, T., Takahashi, T., & Mitsudomi, T. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000157935.28066.35 · Cited by 237
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
Chitale, D., Gong, Y., Taylor, B. S., Broderick, S., Brennan, C., Somwar, R., Golas, B., Wang, L., Motoi, N., Szoke, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.135 · Cited by 230
Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D. S., Tang, X., MacAulay, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007464 · Cited by 228
Hastak, K., Alli, E., & Ford, J. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4521 · Cited by 176
Gene expression patterns associated with p53 status in breast cancer
Troester, M. A., Herschkowitz, J. I., Oh, D. S., He, X., Hoadley, K. A., Barbier, C. S., & Perou, C. M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-276 · Cited by 168
Self-citationGenomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients
Russnes, H. G., Vollan, H. K. M., Lingjærde, O. C., Krasnitz, A., Lundin, P., Naume, B., Sørlie, T., Borgen, E., Rye, I. H., Langerød, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000611 · Cited by 152
Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines
Coldren, C. D., Helfrich, B. A., Witta, S. E., Sugita, M., Lapadat, R., Zeng, C., Barón, A., Franklin, W. A., Hirsch, F. R., Geraci, M. W., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0095 · Cited by 147
Bengtsson, H. L., Wirapati, P., & Speed, T. P. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp371 · Cited by 138
Prognostic significance of grading in lung adenocarcinoma
Barletta, J. A., Yeap, B. Y., & Chirieac, L. R. (2009) · Cancer · doi:10.1002/cncr.24831 · Cited by 136
Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma
Larsen, J. E., Pavey, S. J., Passmore, L. H., Bowman, R., Hayward, N. K., & Fong, K. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2525 · Cited by 122
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Đačić, S., Shuai, Y., Yousem, S. A., Ohori, P. N., & Nikiforova, M. N. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.154 · Cited by 116
hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis
de Wilde, J., Kooter, J. M., Overmeer, R., Claassen-Kramer, D., Meijer, C. J. L. M., Snijders, P. J. F., & Steenbergen, R. D. M. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-271 · Cited by 72
Bryant, C. M., Albertus, D. L., Kim, S., Chen, G., Brambilla, C., Guedj, M., Arima, C., Travis, W. D., Yatabe, Y., Takahashi, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011712 · Cited by 55
Yuan, E., Haghighi, F. G., White, S., Costa, R., McMinn, J. E., Chun, K., Minden, M. D., & Tycko, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3739 · Cited by 55
Weiss, M. B., Vitolo, M. I., Mohseni, M., Rosen, D. M., Denmeade, S. R., Park, B. H., Weber, D. J., & Bachman, K. E. (2010) · Oncogene · doi:10.1038/onc.2010.220 · Cited by 54
ClaNC: point-and-click software for classifying microarrays to nearest centroids
Dabney, A. R. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti756 · Cited by 53
DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors
Walter, V., Nobel, A. B., & Wright, F. A. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq717 · Cited by 34
Self-citation
Cited by
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Systematic pan-cancer analysis of tumour purity
Aran, D., Sirota, M., & Butte, A. J. (2015) · Nature Communications · doi:10.1038/ncomms9971 · Cited by 1,216
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
Li, B., Cui, Y., Diehn, M., & Li, R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1609 · Cited by 514
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Metadata
- Authors
- Wilkerson, M. D., Yin, X., Walter, V., Zhao, N., Cabanski, C. R., Hayward, M. C., Miller, C. R., Socinski, M. A., Parsons, A. M., Thorne, L. B., Haithcock, B. E., Veeramachaneni, N. K., Funkhouser, W. K., Randell, S. H., Bernard, P. S., Perou, C. M., & Hayes, D. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-10
- Volume
- 7
- Issue
- 5
- Pages
- e36530
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2038014733
- Cited by
- 298
- References
- 52
- FWCI
- 17.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.